Ratings Jazz Pharmaceuticals plc Sao Paulo

Equities

J2AZ34

BRJ2AZBDR009

Market Closed - Sao Paulo Other stock markets 09:17:51 2024-05-10 am EDT			5-day change	1st Jan Change
38.72 ^BRL	-0.56%		-.--%	-10.95%

Jul. 10	Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer	CI
Jul. 09	RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company has a low valuation given the cash flows generated by its activity.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JAZZ PHARMACEUTICALS PLC	-10.95%	6.66B	-
ELI LILLY AND COMPANY	+62.66%	854B	C+
NOVO NORDISK A/S	+40.42%	636B	B
JOHNSON & JOHNSON	-4.37%	361B	C+
MERCK & CO., INC.	+17.16%	324B	B-
ABBVIE INC.	+9.87%	301B	C+
ASTRAZENECA PLC	+15.66%	247B	B+
ROCHE HOLDING AG	+4.21%	230B	A+
NOVARTIS AG	+17.90%	228B	B-
AMGEN INC.	+14.86%	177B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes